165 related articles for article (PubMed ID: 35079054)
1. Vaccination of mice with hybrid protein containing Exotoxin S and PcrV with adjuvants alum and MPL protects Pseudomonas aeruginosa infections.
Asadi Karam MR; Badmasti F; Ahmadi K; Habibi M
Sci Rep; 2022 Jan; 12(1):1325. PubMed ID: 35079054
[TBL] [Abstract][Full Text] [Related]
2. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
[TBL] [Abstract][Full Text] [Related]
3. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
Hamaoka S; Naito Y; Katoh H; Shimizu M; Kinoshita M; Akiyama K; Kainuma A; Moriyama K; Ishii KJ; Sawa T
Microbiol Immunol; 2017 Feb; 61(2):64-74. PubMed ID: 28370521
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics analyses for the designation of a hybrid protein against urinary tract infections caused by
Sharbatdaralaei H; Asadi Karam MR; Ahmadi K; Habibi M
J Biomol Struct Dyn; 2022; 40(19):9081-9095. PubMed ID: 34014146
[No Abstract] [Full Text] [Related]
5. Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection.
Li P; Wang X; Sun X; Guan Z; Sun W
mSphere; 2021 Oct; 6(5):e0069921. PubMed ID: 34612675
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
Moriyama K; Wiener-Kronish JP; Sawa T
Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
[TBL] [Abstract][Full Text] [Related]
7. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
Wang Q; Li H; Zhou J; Zhong M; Zhu D; Feng N; Liu F; Bai C; Song Y
Respir Physiol Neurobiol; 2014 Mar; 193():21-8. PubMed ID: 24418353
[TBL] [Abstract][Full Text] [Related]
8. A Live
Aguilera-Herce J; García-Quintanilla M; Romero-Flores R; McConnell MJ; Ramos-Morales F
mSphere; 2019 Apr; 4(2):. PubMed ID: 30996108
[No Abstract] [Full Text] [Related]
9. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection.
Jiang M; Yao J; Feng G
PLoS One; 2014; 9(5):e96609. PubMed ID: 24788626
[TBL] [Abstract][Full Text] [Related]
11. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
Sawa T; Ito E; Nguyen VH; Haight M
Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
[TBL] [Abstract][Full Text] [Related]
12. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.
Baer M; Sawa T; Flynn P; Luehrsen K; Martinez D; Wiener-Kronish JP; Yarranton G; Bebbington C
Infect Immun; 2009 Mar; 77(3):1083-90. PubMed ID: 19103766
[TBL] [Abstract][Full Text] [Related]
13. In-Silico Analysis and Protective Efficacy of the PcrV Recombinant Vaccine against Pseudomonas Aeruginosa in the Burned and PA-Infected BALB/c Mouse Model.
Fakoor MH; Owlia P; Mousavi Gargari SL; Sabokbar A
Iran J Immunol; 2020 Jun; 17(2):121-136. PubMed ID: 32602466
[TBL] [Abstract][Full Text] [Related]
14. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa.
Golpasha ID; Mousavi SF; Owlia P; Siadat SD; Irani S
Bosn J Basic Med Sci; 2015 May; 15(2):15-24. PubMed ID: 26042508
[TBL] [Abstract][Full Text] [Related]
15. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
[TBL] [Abstract][Full Text] [Related]
16. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.
Neely AN; Holder IA; Wiener-Kronish JP; Sawa T
Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685
[TBL] [Abstract][Full Text] [Related]
17. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.
Warrener P; Varkey R; Bonnell JC; DiGiandomenico A; Camara M; Cook K; Peng L; Zha J; Chowdury P; Sellman B; Stover CK
Antimicrob Agents Chemother; 2014 Aug; 58(8):4384-91. PubMed ID: 24841258
[TBL] [Abstract][Full Text] [Related]
18. Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against
Wan C; Zhang J; Zhao L; Cheng X; Gao C; Wang Y; Xu W; Zou Q; Gu J
Front Immunol; 2019; 10():781. PubMed ID: 31068928
[No Abstract] [Full Text] [Related]
19. Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by
Das S; Howlader DR; Zheng Q; Ratnakaram SSK; Whittier SK; Lu T; Keith JD; Picking WD; Birket SE; Picking WL
Front Immunol; 2020; 11():583008. PubMed ID: 33281815
[TBL] [Abstract][Full Text] [Related]
20. Development of a multi-epitope vaccine candidate against
Kalantari H; Habibi M; Ferdousi A; Asadi Karam MR; Mohammadian T
J Biomol Struct Dyn; 2024 Aug; 42(12):6212-6227. PubMed ID: 37489041
[No Abstract] [Full Text] [Related]
[Next] [New Search]
